207 related articles for article (PubMed ID: 35040348)
1. New trends in intravitreal anti-VEGF therapy for ROP.
Beccasio A; Mignini C; Caricato A; Iaccheri B; Di Cara G; Verrotti A; Cagini C
Eur J Ophthalmol; 2022 May; 32(3):1340-1351. PubMed ID: 35040348
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Chandra P
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis.
Ortiz-Seller A; Martorell P; Barranco H; Pascual-Camps I; Morcillo E; Ortiz JL
Surv Ophthalmol; 2024; 69(4):585-605. PubMed ID: 38432359
[TBL] [Abstract][Full Text] [Related]
4. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
6. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
7. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
Stahl A; Sukgen EA; Wu WC; Lepore D; Nakanishi H; Mazela J; Moshfeghi DM; Vitti R; Athanikar A; Chu K; Iveli P; Zhao F; Schmelter T; Leal S; Köfüncü E; Azuma N;
JAMA; 2022 Jul; 328(4):348-359. PubMed ID: 35881122
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.
Ekinci DY; Çelik K
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042
[TBL] [Abstract][Full Text] [Related]
9. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity.
Chang E; Josan AS; Purohit R; Patel CK; Xue K
Ophthalmology; 2022 Dec; 129(12):1389-1401. PubMed ID: 35842190
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of retinopathy of prematurity after ranibizumab treatment.
Wong RK; Hubschman S; Tsui I
Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.
Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
Ital J Pediatr; 2023 Oct; 49(1):136. PubMed ID: 37814332
[TBL] [Abstract][Full Text] [Related]
12. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity.
Cheng Y; Zhu X; Linghu D; Liang J
Acta Ophthalmol; 2020 Dec; 98(8):e1004-e1008. PubMed ID: 32385940
[TBL] [Abstract][Full Text] [Related]
14. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
Chandra P; Kumawat D; Agarwal D; Chawla R
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
[TBL] [Abstract][Full Text] [Related]
15. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.
Chow SC; Lam PY; Lam WC; Fung NSK
Eye (Lond); 2022 Aug; 36(8):1532-1545. PubMed ID: 35017699
[TBL] [Abstract][Full Text] [Related]
16. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
19. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
[TBL] [Abstract][Full Text] [Related]
20. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.
Tsiropoulos GN; Seliniotaki AK; Haidich AB; Ziakas N; Mataftsi A
Int Ophthalmol; 2023 Mar; 43(3):1027-1062. PubMed ID: 36214992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]